Biogen (NASDAQ/BGEN) today announced the appointment of Patrick J. Purcell to the newly created position of Vice President, Chief Information Officer. Mr. Purcell reports to James C. Mullen, Biogen’s President and Chief Executive Officer.

Mr. Purcell, 40, joins Biogen from Sprint, where he worked from 1992 to 2000 in a variety of finance and information technology management capacities, most recently serving as Vice President, IT Planning, Resource & Performance Management for Sprint PCS. Prior to that, he worked at Deloitte & Touche Management Consulting from 1988 to 1992, with primary focus on business and financial planning, financing and operations analysis, and change management in a variety of industries. Mr. Purcell earned his B.S. in Mechanical Engineering (Magna Cum Laude) from Boston University and his M.B.A. in Corporate Finance from The Wharton School of Business at the University of Pennsylvania.

Mr. Mullen said, “We are pleased that an information technology executive with Patrick Purcell’s range of experience is joining Biogen. We are facing a changing healthcare environment and a rapidly evolving industry where information technology plays a significant role. Patrick’s credentials will position him to meet the many challenges of a growing company like Biogen. He will be a valuable addition to the senior management team.”

Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from international sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products ( Prescribing Information ). Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at